Clinical Trial Update: Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC) [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for Trilaciclib in combination with etoposide and carboplatin in extensive-stage small cell lung cancer (Phase 1/2) completed with results…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Etoposide (Etoposide)
• G1T28 (Trilaciclib)
• trilaciclib (trilaciclib)

Snippet

Sponsor: G1 Therapeutics, Inc. | Conditions: Small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2020-07-09